Health · Regenerative Medicine
A drug approved for seizures and nerve pain.
It may also tell your cartilage to stop breaking down and start repairing itself.
Yale researchers have found that lacosamide, a decades-old FDA-approved medication, can both relieve osteoarthritis pain and help reverse cartilage damage — something no currently approved drug can do. The effect gets it dramatically stronger when the medication is delivered directly into the joint through a specially engineered hydrogel, opening a faster, more direct path toward actually treating the disease instead of just masking it.
Cartilage cushions the knee joint — and in osteoarthritis, it wears away faster than the body can rebuild it.
Signal Depth Navigator
A Yale research team led by Chuan-Ju Liu found that lacosamide, an existing FDA-approved medication, can relieve osteoarthritis pain while helping repair damaged cartilage, especially when delivered through a specialized hydrogel injected directly into the joint. This article covers why osteoarthritis isn't simple wear and tear, how a protein called Nav1.7 links pain and cartilage breakdown, why this particular drug stood out, and what still needs to happen before it reaches patients.
Understand
2. Why Osteoarthritis Isn't Just "Wear and Tear" 3. The Protein Nobody Expected to Find in Cartilage 4. One Target, Two Problems Solved at OnceEvaluate
5. Why Lacosamide, Specifically 6. A Dose So Small It Surprised Its Own Researchers 7. The "Leaky Bucket" Problem With Injecting a KneeLook Ahead
8. A Gel That Turns Solid at Body Temperature 9. Why an Old Drug Could Reach Patients Faster 10. What Still Has to Be ProvenFinal Take
11. Manohar InsightA Drug for Seizures That Might Rebuild Your Knee
For millions of people with osteoarthritis, ordinary activities become quietly limited by pain and stiffness.
Over-the-counter pain relievers and steroid injections can ease discomfort for a while. Neither one stops the underlying cartilage from continuing to break down.
Researchers at Yale think they've found something that might actually do both.
In a study published in Bioactive Materials, the team identified lacosamide — an existing, FDA-approved medication — as a genuinely promising osteoarthritis treatment.
It didn't just reduce joint pain. It helped reverse cartilage damage, especially when delivered directly into the joint through a specialized hydrogel.
Lacosamide isn't a new discovery. It's already approved for treating seizures and certain types of nerve pain.
Finding an entirely new use for a drug already proven safe in humans is exactly the kind of shortcut medicine rarely gets handed for free.
"There is a major unmet need in osteoarthritis," says Chuan-Ju Liu, the study's principal investigator and Charles W. Ohse Professor of Orthopaedics & Rehabilitation at Yale.
Why Osteoarthritis Isn't Just "Wear and Tear"
Osteoarthritis gets described casually as a wear-and-tear disease. That label undersells what's actually happening inside the joint.
Cartilage isn't a static, passive cushion. It's actively maintained by cells called chondrocytes.
Chondrocytes constantly balance two jobs at once: building new cartilage, and clearing away old tissue.
In a healthy joint, that balance holds steady for decades. Osteoarthritis throws it off.
Cartilage destruction starts outpacing repair. Slowly, the cushioning layer between bones simply wears thinner than the body can rebuild it.
Eventually, bones begin rubbing directly against each other. That's when the disease can progress toward procedures like total knee replacement.
Right now, no FDA-approved medication can both relieve that pain and stop the underlying breakdown.
Liu is direct about the goal driving this research: "We need therapies that don't just mask pain but actually change how the disease progresses."
The Protein Nobody Expected to Find in Cartilage
This entire discovery hinges on one protein: Nav1.7.
Nav1.7 forms a sodium channel — a tiny gateway embedded in cell membranes that lets cells transmit electrical signals.
For years, scientists believed Nav1.7 lived almost exclusively in nerve cells, specifically the ones responsible for carrying pain signals to the brain.
Liu's team found something nobody expected: the same protein is also highly active inside chondrocytes, the very cells responsible for maintaining cartilage.
That's a genuinely surprising location for a protein everyone assumed belonged strictly to the nervous system.
In healthy joints, Nav1.7 stays relatively quiet inside these cells. In osteoarthritis, it becomes overactive.
That overactivity does two things simultaneously: it amplifies pain signals, and it pushes chondrocytes to break down the very cartilage they're supposed to protect.
One overactive protein, quietly driving both the pain and the tissue damage at the same time.
One Target, Two Problems Solved at Once
Finding one protein responsible for two separate symptoms isn't just an interesting biological detail. It's a genuine strategic opportunity.
Most existing treatments only ever tackle one side of osteoarthritis. Painkillers address discomfort. They do nothing for the cartilage itself.
If Nav1.7 genuinely drives both problems, blocking it might address both at once, using a single mechanism.
Liu describes the discovery in exactly those terms. "When Nav1.7 becomes dysregulated, it contributes to both joint degeneration and pain," he says.
"Our findings suggest that Nav1.7 is a dual-acting target," he continues. "By blocking this single protein, we can potentially quiet the pain nerves and tell the cartilage cells to not only stop breaking down but start repairing as well."
That's a genuinely different treatment philosophy than anything currently approved for the disease.
Not managing two symptoms with two separate approaches. Interrupting one shared mechanism, and letting both benefits follow from it.
That reframing is what turned this from a pain-relief study into something with genuine disease-modifying potential.
Why Lacosamide, Specifically
Identifying Nav1.7 as a target is one thing. Finding the right drug to actually hit it is another.
Rather than inventing a brand-new compound from scratch, Liu's team tested existing sodium channel inhibitors already available for other conditions.
Among those candidates, lacosamide stood apart. It produced strong biological effects at notably low doses.
It also carried a better safety profile than older drugs in the same sodium-channel-inhibitor class.
Repurposing an approved drug rather than developing something entirely new isn't a minor shortcut. It's often the difference between years and decades of development time.
Lacosamide already carries a known safety record in humans, from its existing use in epilepsy and certain nerve pain conditions.
That existing track record meant researchers weren't starting from zero on safety questions that normally take years to answer.
The remaining question was whether it could actually deliver the dual benefit this specific disease target demanded.
A Dose So Small It Surprised Its Own Researchers
Laboratory testing revealed something the team hadn't fully anticipated: lacosamide worked best inside a genuinely narrow dosing window.
At the optimal low concentration, it stimulated production of cartilage-building proteins, while simultaneously limiting tissue breakdown.
Doses that strayed too high, or too low, reduced those benefits noticeably.
"This tells us the system is finely tuned," Liu notes. "There is an optimal range where the drug helps restore balance without overcorrecting."
"What stood out was not just its effectiveness, but how little of a dose was needed," he adds.
The team also discovered lacosamide encourages cells to release two additional protective proteins: HSP70 and midkine.
HSP70 helps cells recover from stress and supports tissue repair. Midkine reduces inflammation and helps shield cartilage from further degeneration.
"These proteins create a supportive environment for cartilage maintenance," Liu explains. "They allow the effects of the drug to extend beyond individual cells and influence the entire tissue."
The "Leaky Bucket" Problem With Injecting a Knee
A promising drug still needs a practical way to actually reach the joint. That turned out to be its own separate challenge.
Oral lacosamide performed well in preclinical testing. But taken as a pill, it circulates throughout the entire body, raising the risk of unwanted side effects elsewhere.
To keep the treatment concentrated where it's actually needed, researchers explored injecting it directly into the knee instead.
That approach ran into an immediate, very physical obstacle.
"The knee joint, which is also the most common location for osteoarthritis, naturally acts like a leaky bucket," Liu explains.
"The body's drainage system can clear out liquids injected into the knee within hours," he adds.
A drug that drains away within hours can't deliver the sustained, weeks-long exposure cartilage repair genuinely requires.
Solving that drainage problem meant the medication itself wasn't enough. The delivery method needed its own breakthrough.
A Gel That Turns Solid at Body Temperature
The team's answer was a thermoresponsive hydrogel, built from Collagen II.
The hydrogel stays liquid in a cool syringe, then firms into a gel once it reaches body temperature — trapping the drug exactly where it's needed.
The material's key property is right in its name: it responds to temperature.
Inside a cool syringe, it stays liquid, easy to inject through a standard needle.
Once it reaches body temperature, inside the joint, it firms into a stable gel almost immediately.
From there, it gradually releases the medication over several weeks, keeping it concentrated exactly where the damage is occurring.
"The hydrogel acts as a local reservoir," Liu says. "It holds the drug in place in the location it is needed most and releases it slowly over time."
"It transforms a daily pill into a long-lasting, local treatment that stays active for a month or longer," he adds.
In preclinical studies, a single hydrogel injection every four weeks outperformed a daily oral dose at preventing cartilage loss.
One monthly injection, beating a pill taken every single day. That's a genuinely meaningful difference for anyone managing a chronic condition long-term.
Why an Old Drug Could Reach Patients Faster
Because lacosamide is already approved for human use, researchers believe it could reach osteoarthritis clinical trials considerably sooner than an entirely new drug.
Brand-new compounds typically require years of safety testing before they can even begin trials for a specific disease.
Lacosamide has already cleared that bar, for different conditions, but the underlying safety data still carries real weight.
There's additional supporting evidence too. Lacosamide has already shown benefits in clinical trials involving patients with nerve pain disorders linked specifically to Nav1.7 mutations.
Those existing human results add real confidence that laboratory findings here could genuinely translate into meaningful benefits for osteoarthritis patients.
This approach also reflects a broader pattern gaining traction across medicine: combining existing drug therapies with advanced biomaterials to improve how treatments actually reach their target.
For patients, that combination could eventually mean fewer procedures, fewer side effects, and longer-lasting protection against ongoing joint damage.
It's also, notably, a path that avoids relying on addictive opioids for long-term pain management.
What Still Has to Be Proven
None of this makes lacosamide an approved osteoarthritis treatment yet. These results come from preclinical studies, not human trials.
Preclinical success is a genuinely necessary step. It's not the same as proof the treatment works safely and effectively in actual osteoarthritis patients.
Human clinical trials specifically for this combination — lacosamide plus the Collagen II hydrogel — still need to happen.
Those trials will need to confirm the same narrow, finely-tuned dosing window holds up in real patients, not just in laboratory models.
They'll also need to confirm the hydrogel delivery system performs as reliably in human joints as it did in preclinical testing.
Liu frames the broader ambition clearly. "We are not just developing a treatment," he says. "We are developing a system that allows the medicine to work more effectively where it matters most."
"Our goal is to move beyond symptom control and towards true disease modification," he continues. "This effort brings us closer to that reality."
That's a genuinely ambitious goal, and an honest one about the distance still left to travel toward it.
Manohar Insight
What strikes me most here is how much value was hiding inside a drug nobody was looking at for this purpose.
Lacosamide has existed for years, quietly treating seizures and nerve pain, with nobody suspecting it might also speak to cartilage cells.
That's the quiet promise of drug repurposing research. Sometimes the answer isn't a molecule that doesn't exist yet. It's one already sitting on a pharmacy shelf, doing a different job.
There's also something worth noticing in how precisely tuned this treatment turned out to be. Too much drug hurt. Too little did nothing. Only a narrow window actually worked.
That kind of precision is exactly why the hydrogel delivery system matters as much as the drug discovery itself.
A brilliant molecule, delivered carelessly, can fail for reasons that have nothing to do with the biology.
Getting both pieces right, the target and the delivery, at the same time, is genuinely rare in early-stage research like this.
The real breakthrough here isn't a new drug. It's an old one, finally asked the right question.
Join the Signal
If a decades-old seizure medication can be repurposed to repair cartilage instead of just masking joint pain, what other overlooked drugs do you think might be hiding a second use nobody has tested yet? Share your take in the comments.
#Osteoarthritis #RegenerativeMedicine #DrugRepurposing #Cartilage #Hydrogel #JointHealth #MedicalResearch #ScienceNews #KMManoharInsights
Explore More
Injectable Bone Cements 4.0: The Nano-Biomed Breakthrough Redefining Bone Regeneration, Drug Delivery & Future HealthcareAnother story about engineering exactly how a treatment reaches bone and joint tissue, not just what the treatment is.
GLP-1 Revolution 2026: How Ozempic, Wegovy & Mounjaro Are Disrupting Bariatric MedicineAnother drug that found an entirely new purpose well beyond its original approval — a familiar pattern in modern medicine.
Gene Therapy for Heart Failure: The New Frontier in Cardiac RegenerationA different organ, a different approach, but the same underlying ambition — treating disease progression, not just its symptoms.
Gecko-Inspired Smart Janus Bandage: The Scar-Minimizing Wound Healing BreakthroughAnother regenerative medicine story built around a smart material designed to support the body's own repair process.
Moisture-Powered Wound Healing: How Hygroscopic Electricity Could Transform Future CareA different tissue-repair breakthrough, powered by an equally unexpected mechanism hiding in plain sight.
About the Author
K M Manohar is an independent Sci-Tech writer and research curator who explains breakthrough discoveries that are shaping the future of technology.
Comments
Post a Comment